Merck & Co., Inc. Stock Forecast, Price & News

$78.33
+0.48 (+0.62 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.47
$78.67
50-Day Range
$72.40
$79.66
52-Week Range
$71.71
$87.80
Volume10.98 million shs
Average Volume11.70 million shs
Market Capitalization$198.34 billion
P/E Ratio28.38
Dividend Yield3.34%
Beta0.41
30 days | 90 days | 365 days | Advanced Chart
Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.


Merck & Co., Inc. logo

About Merck & Co., Inc.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.56 out of 5 stars

Medical Sector

22nd out of 2,210 stocks

Pharmaceutical Preparations Industry

13th out of 867 stocks

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view top-rated stocks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 22,070,000 shares, an increase of 17.2% from the May 31st total of 18,830,000 shares. Based on an average daily trading volume, of 11,710,000 shares, the short-interest ratio is currently 1.9 days.
View Merck & Co., Inc.'s Short Interest
.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Merck & Co., Inc.
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Thursday, April, 29th. The company reported $1.40 EPS for the quarter, missing the consensus estimate of $1.63 by $0.23. The company had revenue of $12.08 billion for the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 54.15%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.50 EPS.
View Merck & Co., Inc.'s earnings history
.

How has Merck & Co., Inc.'s stock been impacted by COVID-19?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRK shares have decreased by 1.2% and is now trading at $78.33.
View which stocks have been most impacted by COVID-19
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a dividend on Tuesday, June 1st. Stockholders of record on Friday, June 4th will be paid a dividend of $0.65 per share on Wednesday, June 2nd. This represents a yield of 3.42%. The ex-dividend date is Thursday, June 3rd.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.34%. Merck & Co., Inc. does not yet have a strong track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 41.34% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share (EPS) guidance of 6.480-6.680 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.570. The company issued revenue guidance of $51.80 billion-$53.80 billion, compared to the consensus revenue estimate of $52.51 billion.

What price target have analysts set for MRK?

11 analysts have issued 12 month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $76.79 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.47 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Robert M. Davis, President, Chief Executive Officer & Director
  • Caroline A. Litchfield, Chief Financial Officer & Executive Vice President
  • Sandy Tremps, Vice President-R&D IT CIO
  • Dave Williams, Chief Information & Digital Officer
  • Franklin K. Clyburn, Executive VP & President-Human Health

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Marathon Asset Management LLP (0.09%), State of Alaska Department of Revenue (0.03%), Manning & Napier Group LLC (0.03%), Cacti Asset Management LLC (0.03%), Oregon Public Employees Retirement Fund (0.02%) and Gofen & Glossberg LLC IL (0.02%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Heritage Wealth Advisors, TCW Group Inc., State of Alaska Department of Revenue, Welch & Forbes LLC, Marshall Financial Group LLC, Terril Brothers Inc., Hodges Capital Management Inc., and Raymond James Trust N.A.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, Manning & Napier Group LLC, Brookstone Capital Management, Bright Rock Capital Management LLC, Oregon Public Employees Retirement Fund, Allied Investment Advisors LLC, IFM Investors Pty Ltd, and DAVENPORT & Co LLC.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $78.33.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $198.34 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 74,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.